Palvella Therapeutics (PVLA) Capital Expenditures (2014 - 2023)

Palvella Therapeutics (PVLA) has 10 years of Capital Expenditures data on file, last reported at -$13000.0 in Q4 2023.

• On a quarterly basis, Capital Expenditures fell 101.29% year-over-year to -$13000.0 in Q4 2023; TTM through Sep 2024 was -$13000.0, a 101.09% decrease from a year earlier, with the FY2023 full-year figure at $171000.0, down 83.57% from the prior year.
• Capital Expenditures for Q4 2023 stood at -$13000.0, down from $69000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for PVLA reached as high as $1.9 million in Q1 2020 and fell as low as -$987000.0 in Q3 2022.
• Historically, Capital Expenditures has averaged $367450.0 across 5 years, with a median of $287000.0 in 2019.
• On a YoY basis, Capital Expenditures climbed as much as 1492.56% in 2020 and fell as far as 462.07% in 2020.
• Year by year, Capital Expenditures stood at $1.2 million in 2019, then sank by 50.85% to $578000.0 in 2020, then slumped by 40.83% to $342000.0 in 2021, then surged by 195.32% to $1.0 million in 2022, then sank by 101.29% to -$13000.0 in 2023.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$13000.0 in Q4 2023, $69000.0 in Q3 2023, and $67000.0 in Q2 2023.